olmutinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5210 1353550-13-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • olmutinib
  • olita
  • BI 1482694
  • HM 61713
  • olmutinib hydrochloride
  • olmutinib HCl
Olmutinib is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) for the treatment of non-small cell lung cancer (NSCLC). Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymatic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.
  • Molecular weight: 486.59
  • Formula: C26H26N6O2S
  • CLOGP: 5.05
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 2
  • TPSA: 82.62
  • ALOGS: -4.79
  • ROTB: 7

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.790 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.873 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 5.984 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 136.144 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 2.640 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 5.290 % Moderate 0.72
herg hERG pIC50 5.686 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 5.808 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 39.174 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 1.200 % Moderate 0.72
kinase-safety-class AAK1,ABL1,ABL2,ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK16,CDK4,CDK9,CHEK1,CHEK2,CLK4,CSF1R,CSK,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB1,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FYN,GAK,GRK1,GRK2,GSK3B,IGF1R,INSR,INSRR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK10,MAPK12,MAPK3,MAPK7,MAPK8,MAPK9,MARK1,MARK4,MELK,MET,MINK1,MKNK2,NTRK1,NTRK2,PAK1,PAK2,PAK4,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CD,PIM3,PLK1,PLK2,PLK3,PLK4,PRKAA2,PRKCD,PRKCZ,PRKDC,PTK2,PTK6,RET,RIPK3,SIK2,SIK3,SRC,STK17A,STK33,STK4,SYK,TEK,TGFBR1,TNIK,TNK1,TTK,TYRO3,ULK1,ULK2,YES1,ZAP70 129
kinase-selectivity-class AAK1,ACVR2B,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BTK,CAMK2A,CAMK2D,CLK4,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FYN,GAK,IGF1R,INSR,IRAK1,IRAK3,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K3,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K3,MAPK12,MAPK7,MARK4,MELK,MET,MINK1,MST1R,NTRK1,NUAK1,PDGFRB,PDK1,PDK4,PIM3,RET,RIPK3,SIK2,SIK3,SRC,STK16,STK33,SYK,TEK,TNIK,TNK1,TTK,TYRO3,ULK1,YES1 76
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 9.099 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 114.551 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 1.060 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 17.219 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 5.250 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 133.045 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 7.440 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 0.830 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 3.890 uM Moderate 0.72

Approvals:

DateAgencyCompanyOrphan
None Korean Food and Drug Administration (KFDA)

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EB06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 8 drugs
afatinibdacomitiniberlotinibgefitinibicotiniblazertinibmobocertinibosimertinib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.82 acidic
pKa2 8.43 Basic
pKa3 5.75 Basic
pKa4 1.26 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Epidermal growth factor receptor Kinase INHIBITOR IC50 8.04 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Tyrosine-protein kinase BTK Kinase IC50 9 CHEMBL

External reference:

IDSource
CHL9B67L95 UNII
1842366-97-5 SECONDARY_CAS_RN
C4301624 UMLSCUI
CHEBI:755885 CHEBI
CHEMBL3786343 ChEMBL_ID
54758501 PUBCHEM_CID
DB13164 DRUGBANK_ID
D10859 KEGG_DRUG
CHEMBL3989930 ChEMBL_ID
10093 INN_ID
C000617753 MESH_SUPPLEMENTAL_RECORD_UI
9196 IUPHAR_LIGAND_ID
CHL9B67L95 INXIGHT DRUGS

Pharmaceutical products:

None